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patients. The plans allow geometrical ad-hoc adaptation to large 
interfractional deformations of patient geometry.  
Materials and Methods: Patients with intermediate or high-risk 
prostate cancer are normally treated using VMAT technique with 
Simultaneously Integrated Boost at our department. The CTV is 
defined as the prostate and the base of seminal vesicles. The Boost 
(PTV) is obtained by expanding the CTV by 5 (10) mm. Prescription 
doses to PTV and Boost are respectively 60.1 and 74 Gy given in 33 
fractions. 
Our method of IMAT for prostate cancer uses three arcs. We analyze 
the geometry of the structures of interest (PTV and rectum), and 
generate segments to deliver three fluence steps: conformal (Step 0, 
first arc), sparing the rectum (Step 1, second arc), and narrow 
segments compensating for the underdosage in the PTV due to rectum 
sparing (Step 2, third arc). The width of Step 2 segments is calculated 
for every MLC leaf pair based on the PTV and rectum geometry in the 
corresponding CT layer to have best dose homogeneity. The segments 
are then fed into the DMPO engine of Pinnacle for weight optimization 
and fine-tuning of the form. We call this method '2-Step IMAT'. 2-Step 
IMAT and reference VMAT plans show highly equivalent target 
coverage, rectum sparing, and dosimetric quality, with 2-Step IMAT 
taking on average 230 sec to deliver vs 100 sec for VMAT. 
We adapt 2-Step IMAT plans to changed geometry preserving the 
number of Monitor Units (MU) calculated for each segment at initial 
geometry. The leaves of Step 0 segments follow the edges of the PTV 
in Beam Eye View to keep PTV conformally irradiated. The leaves of 
Step 1 segments follow the edges of the rectum to keep it spared. For 
Step 2 segments, the opening of each leaf pair is adapted to the 
geometry change in the corresponding CT layer to have best dose 
homogeneity under the condition of MU preservation.  
Results: Four adaptation cases have been considered. The ones having 
best and worst improvement of target coverage between relocated 
and adapted plan are shown in Fig.1 a,b and Tab. 1. The target 
coverage is measured by SD index which sums up violations of dose 
requirements for Boost and PTV-Boost:  
 
To characterize rectum sparing we measure absolute rectum volumes 
cut out by 95%-, 80%-, and 50%-isodose.  
 
 
Fig.1. DVHs for the adaptation cases with the best (a) and the worst 
(b) target coverage: dotted – relocation, thin – new optimization, 
thick – adaptation. 
 Tab.1. Evaluation for Fig.1. 
 
Conclusions: The 2-Step IMAT method delivers prostate plans 
equivalent to the reference VMAT plans. On the expense of 2-3 longer 
delivery time 2-Step IMAT plans offer the possibility to adapt to large 
interfractional changes of patient geometry. 
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Purpose/Objective: Concurrent chemoradiotherapy has been a 
standard treatment for good performance status patients with 
unresectable stage III non–small cell lung cancer (NSCLC). However, 
the toxicities were not neglected. To evaluate pemetrexed in 
combination with cisplatin in these patients, a randomized phase III 
study of concurrent cisplatin with pemtrexed or vinorelbine and late 
course accelerated hyperfractionated radiotherapy (LCAHRT) was 
performed. 
Materials and Methods: Total of 86 patients were randomly assigned 
to two concurrent regimens beforeMarch 2012. Arm1 included 
cisplatin at 25 mg/m2 on days 1-3, 22-24 and vinorelbine at 25 mg/m2 
on days 1,8 and 22,29 with concurrent late course accelerated 
hyperfractionated radiotherapy. Arm 2 used cisplatin at 25 mg/m2 on 
days 1-3, 22-24 and pemtrexed at 500 mg/m2 on days 1 and 22 with 
the same radiotherapy protocol. The primary endpoint was overall 
survival (OS), and secondary endpoints included toxicities. Kaplan–
Meier analyses were used to assess survival, and toxic effects were 
examined using the Pearson Chi-Square test. All statistical tests were 
two-sided. 
Results: 84 patients were analyzed for 2 patients in arm 1 were not 
finished treatment according to the protocol. The mean radiation 
dose in arms 1–2 was 66.2±7.5 Gy and 67.9±7.4 Gy. 76 patients used 2 
cycle concomitant chemotherapy, 4 cases 3 cycles, and 4 ones 1 cycle 
(3 in arm 1 and 1 in arm 2). Median OS were 23 and 25 months for 
arms 1 and 2, respectively (p=0.224). Concerning toxicities of grade 2 
or more in the arms 1 and 2, the white blood cell was 32/41 and 
20/43 (p=0.003), esophagitis 14/41 and 10/43 (p=0.269), pneumonitis 
8/41 and 6/43 (p=0.494), vomiting 13/41 and 9/43 (p=0.261), 
hemotoblatin 8/41 and 5/43 (p=0.318), platelet 9/41 and 5/43 
(p=0.204), respectively. 
Conclusions: Concurrent cisplatin with pemtrexed and LCAHRT was as 
effective as with vinorelbine for unresectable stage III non–small cell 
lung cancer, however, the treatment compatibility was better.  
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